Combination Chemotherapy Plus Surgery and Radiation Therapy in Treating Patients With Ewing's Sarcoma. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.
|Phase III||Treatment||Closed||35 and under||GER-GPOH-EICESS-92|
MRC-EICESS-92, EU-92030, NCT00002516, EU-205116, UKCCSG-ET1993-02
I. Determine whether morbidity can be reduced while preserving survival by substituting cyclophosphamide for ifosfamide in adjuvant combination chemotherapy in standard-risk patients with Ewing's sarcoma or peripheral neuroectodermal tumor (PNET). II. Determine whether survival is improved without unacceptable toxicity for high-risk patients with Ewing's sarcoma or PNET by the addition of etoposide to the VAIA regimen (vincristine/doxorubicin/ifosfamide/dactinomycin). III. Evaluate the impact of surgery and conventional vs. hyperfractionated radiotherapy (definitive and adjuvant) on local control, overall survival, and morbidity in these patients. IV. Relate treatment outcome with patient characteristics, histologic subtype at diagnosis, and histologic response to neoadjuvant treatment. V. Evaluate prospectively ifosfamide-induced nephrotoxicity and doxorubicin-induced cardiotoxicity.
Biopsy-proven Ewing's sarcoma, atypical Ewing's sarcoma, and peripheral neuroectodermal tumors No soft tissue Ewing's sarcoma or other small cell sarcomas of soft tissue Such patients should be treated on the appropriate national Soft Tissue Sarcoma Protocol Treatment must begin within 3 weeks after diagnostic biopsy Registration must occur within 6 weeks after initiation of treatment
No prior therapy, including primary definitive local therapy
Age: Not over 35
It is anticipated that 600 patients (200 standard-risk and 400 high-risk) will be accrued over 4 years.
Randomized study. Patients are initially stratified as STANDARD RISK (tumor volume at diagnosis < 100 ml) and HIGH RISK (tumor volume at diagnosis at least 100 ml or, if < 100 ml, metastasis present). All patients receive 14 courses of chemotherapy, administered q 3 weeks throughout protocol treatment. Standard-risk patients receive 4 courses of NEOADJUVANT CHEMOTHERAPY on Regimen A, while high-risk patients are randomized on Arms I and II for 4 courses of neoadjuvant chemotherapy. LOCAL THERAPY is usually initiated on week 12, after 4 courses of neoadjuvant chemotherapy, and consists of either total removal of the tumor-bearing compartment, intracompartmental surgery (with or without adjuvant radiotherapy), or definitive radiotherapy alone; the choice is dictated by the site, tumor size, and patient age, among other variables. Postoperatively, all patients receive 10 courses of ADJUVANT CHEMOTHERAPY (plus adjuvant radiotherapy when given); standard-risk patients are randomized on Arms III and IV, while high-risk patients receive the same regimen to which they were assigned at initial randomization. When given, adjuvant radiotherapy begins on week 19 and is administered concurrently with chemotherapy. As a variant of this general plan, patients with < 50% regression of the soft tissue component of their tumors at restaging after 2 courses of neoadjuvant chemotherapy (slow response) may receive preoperative irradiation, beginning on week 7, concomitantly with the third and fourth courses of chemotherapy. The following acronyms are used: CTX Cyclophosphamide, NSC-26271 DACT Dactinomycin, NSC-3053 DOX Doxorubicin, NSC-123127 IFF Ifosfamide, NSC-109724 Mesna Mercaptoethane sulfonate, NSC-113891 VCR Vincristine, NSC-67574 VP-16 Etoposide, NSC-141540 NEOADJUVANT CHEMOTHERAPY. Regimen A (Standard risk): Alternating 3-Drug Combination Chemotherapy Regimens. VAIA: VCR/DOX/IFF alternating with VCR/DACT/IFF. Arm I (High risk): Alternating 3-Drug Combination Chemotherapy Regimens. VAIA: VCR/DOX/IFF alternating with VCR/DACT/IFF. Arm II (High-risk): Alternating 4-Drug Combination Chemotherapy Regimens. EVAIA: VP-16/VCR/DOX/IFF alternating with VP-16/VCR/DACT/IFF. LOCAL THERAPY. Surgery: Resection of entire tumor-bearing compartment, including bone and soft tissue, when possible, is the treatment of choice. The range of possible surgical procedures includes: radical resection (e.g., amputation), wide resection (en bloc removal of the entire tumor-bearing compartment), marginal surgery (en bloc removal, but resection line runs through pseudocapsule and microscopic residual disease is likely), intralesional resection (tumor incised with contamination of surgical field), and no resection. Radiotherapy: There are 3 settings in which radiotherapy is delivered in these patients: as definitive treatment when definitive surgery is not feasible, as postoperative adjuvant treatment, and preoperatively in patients with a slow response to neoadjuvant chemotherapy. Patients who are to receive definitive and postoperative adjuvant treatment are randomized between conventional fractionation and hyperfractionated accelerated split-course delivery; individuals receiving preoperative irradiation are not randomized for radiotherapy schedule but are assigned nonrandomly to receive the hyperfractionated accelerated split-course scheme (conventional fractionation requires that DOX and DACT be eliminated from concomitant chemotherapy, whereas these agents can be continued during the hyperfractionated schedule). Individual institutions may elect not to randomize for the radiotherapy fractionation scheme, i.e., to treat all patients on one schedule or the other; in such institutions, all patients must follow the same scheme, decided upon prior to treatment of the first patient. Use of photons with energies of 4-6 MV (including Co60) is recommended for extremity lesions, and 6-15 MV energies are recommended for trunk lesions; electrons may be considered for small superficial boosts, but are not adequate as a sole modality. ADJUVANT THERAPY. Arm III (Standard risk): Alternating 3-Drug Combination Chemotherapy Regimens. VACA: VCR/DOX/CTX alternating with VCR/DACT/CTX. Arm IV (Standard risk): Alternating 3-Drug Combination Chemotherapy Regimens. VAIA: VCR/DOX/IFF alternating with VCR/DACT/IFF. High-risk patients continue with 10 additional courses of VAIA or EVAIA according to original randomization. Adjuvant Radiotherapy, when administered, begins on week 19, and is given concomitantly with chemotherapy.Published Results
Sari N, Toğral G, Cetindağ MF, et al.: Treatment results of the Ewing sarcoma of bone and prognostic factors. Pediatr Blood Cancer 54 (1): 19-24, 2010.[PUBMED Abstract]
Paulussen M, Craft AW, Lewis I, et al.: Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. J Clin Oncol 26 (27): 4385-93, 2008.[PUBMED Abstract]
Whelan J, McTiernan A, Weston C, et al.: Consequences of different approaches to local treatment of Ewing's sarcoma within an international randomised controlled trial: analysis of EICESS-92. [Abstract] J Clin Oncol 24 (Suppl 18): A-9533, 528s, 2006.
Paulussen M, Craft AW, Lewis I, et al.: Ewing tumor of bone - updated report of the European Intergroup Cooperative Ewing's Sarcoma Study EICESS 92. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-1568, 2002.Related Publications
Dunst J, Jürgens H, Sauer R, et al.: Radiation therapy in Ewing's sarcoma: an update of the CESS 86 trial. Int J Radiat Oncol Biol Phys 32 (4): 919-30, 1995.[PUBMED Abstract]
Nowak-Göttl U, Schaudin E, Hoffmann C, et al.: Intraoperative clotting factor dilution and activated hemostasis in children with Ewing's sarcoma or osteosarcoma: a prospective longitudinal study. Haematologica 80 (4): 311-7, 1995 Jul-Aug.[PUBMED Abstract]
Zoubek A, Dockhorn-Dworniczak B, Delattre O, et al.: Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients? J Clin Oncol 14 (4): 1245-51, 1996.[PUBMED Abstract]
Boos J, Krümpelmann S, Schulze-Westhoff P, et al.: Steady-state levels and bone marrow toxicity of etoposide in children and infants: does etoposide require age-dependent dose calculation? J Clin Oncol 13 (12): 2954-60, 1995.[PUBMED Abstract]
Dunst J, Jabar S, Paulussen M, et al.: [Local therapy of Ewing sarcoma: radiotherapy aspects] Klin Padiatr 206 (4): 277-81, 1994 Jul-Aug.[PUBMED Abstract]
Hoffmann C, Jabar S, Ahrens S, et al.: [Prognosis in Ewing sarcoma patients with initial pathological fractures of the primary tumor site] Klin Padiatr 207 (4): 151-7, 1995 Jul-Aug.[PUBMED Abstract]
Nowak-Göttl U, Kehrel B, Budde U, et al.: Acquired von Willebrand disease in malignant peripheral neuroectodermal tumor (PNET). Med Pediatr Oncol 25 (2): 117-8, 1995.[PUBMED Abstract]
Ozaki T, Lindner N, Hoffmann C, et al.: Ewing's sarcoma of the ribs. A report from the cooperative Ewing's sarcoma study. Eur J Cancer 31A (13-14): 2284-8, 1995.[PUBMED Abstract]
Dockhorn-Dworniczak B, Schäfer KL, Dantcheva R, et al.: Diagnostic value of the molecular genetic detection of the t(11;22) translocation in Ewing's tumours. Virchows Arch 425 (2): 107-12, 1994.[PUBMED Abstract]
Jürgens HF: Ewing's sarcoma and peripheral primitive neuroectodermal tumor. Curr Opin Oncol 6 (4): 391-6, 1994.[PUBMED Abstract]
Shi LR, Eichelbauer D, Borchard F, et al.: Specificity and function of monoclonal antibodies directed against Ewing sarcoma cells. Cancer Immunol Immunother 38 (3): 208-13, 1994.[PUBMED Abstract]
Trial Lead Organizations
Klinik und Poliklinik fuer Kinder und Jugendmedizin - Universitaetsklinikum Muenster
|Heribert Juergens, MD, Protocol chair|
Medical Research Council's Working Party on Leukemia in Adults and Children
|Alan Craft, MD, Protocol chair|
|Official Title||EUROPEAN INTERGROUP COOPERATIVE EWING'S SARCOMA STUDY [EICESS 92]|
|Trial Start Date||1992-07-01|
|Registered in ClinicalTrials.gov||NCT00002516|
|Date Submitted to PDQ||1992-07-01|
|Information Last Verified||2010-01-08|
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol.